Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?
Family Practice · 07.02.2026 · 43 (2)
DOI: 10.1093/fampra/cmag008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Family Practice, online erschienen am 26.02.2026. Verfasst von Mehmet Yildiz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Giresun Provincial Health Directorate, Bulancak Sehit Er Enver Erdogan Family Health Center, Giresun 28300, Türkiye. Hauptthemen laut MEDLINE: Liver Cirrhosis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
FINDRISC is a non-invasive, easy-to-use, and free screening tool developed to estimate the 10-year risk of developing type 2 diabetes mellitus (T2DM).
Objective
This study aimed to investigate whether FINDRISC can also predict liver fibrosis risk, as measured by the fibrosis-4 index (FIB-4) in individuals without a diagnosis of T2DM.
Methods
This retrospective cross-sectional study included 1329 adults aged ≥18 years without prior T2DM, based on records from a Family Health Center in Turkey. The FINDRISC results used in T2DM screening were analyzed retrospectively from patient records. FINDRISC scores were calculated from questionnaire results, and FIB-4 was derived from laboratory data (age, alanine aminotransferase, aspartate aminotransferase, platelet count). Chi-square, correlation, and regression analyses were performed, adjusting for gender, smoking, alcohol use, physical activity, and marital status.
Results
Mean FINDRISC scores and FIB-4 were 11.88 ± 6.22 and 1.01 ± 0.80, respectively. Higher FINDRISC categories were associated with older age, female sex, non-smoking, physical inactivity, and obesity. A moderate positive correlation was observed between FINDRISC and FIB-4 (rho = 0.427, P < 0.001). In multivariable regression, FINDRISC emerged as an independent predictor of FIB-4 (β = 0.250, P < 0.001), increasing model variance explained from 6.4% to 12.3%.
Conclusion
FINDRISC, beyond its established role in T2DM risk stratification, may serve as a dual, non-invasive, and free screening tool to identify individuals at increased risk of liver fibrosis. Thanks to its simplicity and self-administered nature, individuals can easily complete the questionnaire at home, enabling early diagnosis of both T2DM and liver fibrosis risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Family Medicine, Giresun Provincial Health Directorate, Bulancak Sehit Er Enver Erdogan Family Health Center, Giresun 28300, Türkiye.
- Department of Midwifery, Giresun University Faculty of Health Sciences, Giresun, Türkiye.
- Independent Researcher, İstanbul, Türkiye.
- Department of Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, Istanbul, Türkiye.
- Department of Internal Medicine, Sakarya Training and Research Hospital, Sakarya, Türkiye.
- Department of General Surgery, Giresun University Faculty of Medicine, Giresun, Türkiye.
ORCID-Profile: Mehmet Yildiz
Zitieren
APA
Yildiz, M., Yiğitbaş, Ç., Genç, A. C., Türkoğlu Genç, F., Zafer, E., Muhtaroğlu, A., Acar, B., Aslan, S., Kuloğlu, E., & İşsever, K. (2026). Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?. Family Practice, 43(2). https://doi.org/10.1093/fampra/cmag008
Vancouver
Yildiz M, Yiğitbaş Ç, Genç AC, Türkoğlu Genç F, Zafer E, Muhtaroğlu A, et al. Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?. Family Practice. 2026;43(2). doi:10.1093/fampra/cmag008
BibTeX
@article{Yildiz2026,
author = {Yildiz, Mehmet and Yiğitbaş, Çağla and Genç, Ahmed Cihad and Türkoğlu Genç, Fevziye and Zafer, Enes and Muhtaroğlu, Ali and Acar, Berkan and Aslan, Sefer and Kuloğlu, Ersin and İşsever, Kubilay},
title = {Can the Finnish Diabetes Risk Score (FINDRISC) be used to predict liver fibrosis risk instead of the fibrosis-4 index (FIB-4)?},
journal = {Family Practice},
year = {2026},
volume = {43},
number = {2},
doi = {10.1093/fampra/cmag008}
}
EUVIMED